WO1998044099A2 - Methodes de detection d'interactions entre plusieurs proteines - Google Patents
Methodes de detection d'interactions entre plusieurs proteines Download PDFInfo
- Publication number
- WO1998044099A2 WO1998044099A2 PCT/FR1998/000685 FR9800685W WO9844099A2 WO 1998044099 A2 WO1998044099 A2 WO 1998044099A2 FR 9800685 W FR9800685 W FR 9800685W WO 9844099 A2 WO9844099 A2 WO 9844099A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- proteins
- transcription
- determined
- host cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 224
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 201
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000003993 interaction Effects 0.000 title claims description 41
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 35
- 230000005764 inhibitory process Effects 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims description 67
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 64
- 238000013518 transcription Methods 0.000 claims description 60
- 230000035897 transcription Effects 0.000 claims description 60
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 32
- 229930182817 methionine Natural products 0.000 claims description 32
- 108700008625 Reporter Genes Proteins 0.000 claims description 31
- 230000004927 fusion Effects 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 18
- 230000004568 DNA-binding Effects 0.000 claims description 17
- 230000004913 activation Effects 0.000 claims description 17
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 14
- 230000004060 metabolic process Effects 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 230000000754 repressing effect Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000007246 mechanism Effects 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000014726 immortalization of host cell Effects 0.000 claims description 5
- 230000009073 conformational modification Effects 0.000 claims description 4
- 230000002596 correlated effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 claims description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 51
- 239000013612 plasmid Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 21
- 101150059448 cdk7 gene Proteins 0.000 description 16
- 102100036883 Cyclin-H Human genes 0.000 description 14
- 108010068237 Cyclin H Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 10
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 9
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 9
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 6
- 108091006106 transcriptional activators Proteins 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 102100039556 Galectin-4 Human genes 0.000 description 5
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 101150009006 HIS3 gene Proteins 0.000 description 4
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- KUWPCJHYPSUOFW-SCWFEDMQSA-N (2r,3r,4s,5r)-2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)OC1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-SCWFEDMQSA-N 0.000 description 3
- 102100032863 General transcription factor IIH subunit 3 Human genes 0.000 description 3
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 3
- 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 description 3
- 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 description 3
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 description 3
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 1
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 description 1
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 description 1
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 1
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 description 1
- 101000582546 Homo sapiens Methylosome protein 50 Proteins 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 101150007280 LEU2 gene Proteins 0.000 description 1
- 101800000507 Non-structural protein 6 Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 108010089576 carboxy-terminal domain kinase Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 101800000629 p34 Proteins 0.000 description 1
- 101800002664 p62 Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to methods of detecting or identifying proteins involved in the formation of a protein complex, or in inhibiting the formation of a protein complex.
- the double-hybrid system is based on the reconstitution of a transcriptional activator in yeast (Fields S. and Song O., 1989; Chien C.-T. et al., 1991).
- a first protein is cloned in fusion with the DNA binding domain, while a second protein is cloned in fusion with the transcription activation domain.
- a transcriptional activator is formed allowing the transcription of reporter genes.
- a triple-hybrid system repeating the principle of the double-hybrid, by inserting into the vectors used a DNA sequence coding for a third partner, has been developed by Zhang and Lautar (Zhang J. et al., 1996).
- One of the aims of the present invention is precisely to provide new methods for studying interactions between proteins, not requiring the implementation of two separate experiments, these methods therefore being simpler to implement, faster. and more reliable than the methods currently proposed.
- the subject of the invention is the use of at least one conditional promoter for the implementation of a method for detecting one (or more) protein (s) (or polypeptides) interacting directly or indirectly with at least two other proteins (or polypeptides) as part of the formation of a protein complex, or the inhibition of the formation of a protein complex.
- any protein catalyzing the formation of a protein complex between at least two proteins without associating with the latter to form a protein complex, in particular by a mechanism of conformational modification of one or more of the partners of the protein complex .
- conditional promoters capable of being used in the context of the present invention, there may be mentioned: - the Met25 promoter (Kerjan P. et al, 1986), which can be regulated as a function of the methionine concentration, or
- the subject of the invention is also any method of detecting a protein as defined above interacting with at least two determined proteins, within the framework of the formation of a protein complex, or of the inhibition of the formation of '' a protein complex, characterized in that it
- the method described above for detecting a protein interacting directly or indirectly with at least two determined proteins comprises: a step of transformation of host cells, the genome of which contains one or more reporter genes, with a or several vectors, so that the genome of these host cells contains:
- the DNA sequence encoding said tested protein capable of interacting with at least two determined proteins, the transcription of this DNA sequence being placed under the control of a conditional promoter
- transformation of host cells with a vector in the above and what follows, is meant any method making it possible to add to the genome of said cells, the content of DNA sequences of a vector, in particular of the plasmid type; the resulting host cells are designated in what piecede and what follows by the expression "transformed host cells"
- genome of a cell one understands the whole of the DNA contained in a cell, has the DNA of chromosomes, mitochond ⁇ es and episomes
- the method of the invention has the advantage of not comprising two separate experiments as described above, including one experiment serving as a negative control by parallel culture of host cells treated with vectors not containing a sequence. of DNA encoding the piote e tested, for the purpose of comparison with the step of culturing tianstorme host cells with vectors containing all of the DNA sequences encoding the pi oteins capable of interacting with each other
- the host cells cultured in the method of the present invention either as a negative control (or an internal control), or for demonstrating an interaction between the proteins, are transformed by the same vectors, thus avoiding lead to erroneous results, as indicated above in the context of the methods currently proposed in this field
- control is internal to the experiment, which makes these methods particularly suitable for screening a cDNA library, or a degenerate synthetic library.
- oligonucleotides which may contain a
- a more particular subject of the invention is any method such as above, in which ⁇ ⁇ - two of the proteins encoded by the DNA sequences contained in the
- the other of these proteins, or at least one of the other proteins encoded by the DNA sequence or sequences contained in the above-mentioned vector (s), is encoded by a DNA sequence the transcription of which is under the control of
- the two determined proteins, or at least two of said determined pioteins, encoded by the DNA sequences contained in the vector (s) used for the transformation of said host cells are in fusion, for one of them, with a DNA binding domain, and for the other, with a transcription activation domain, the transcription of the DNA sequences encoding these two fusion proteins being under the control of constitutive promoters.
- the abovementioned method of the invention can be carried out using a vector containing all of the DNA sequences coding for the proteins in question, or preferably using several vectors constructed in such a way that:
- - one of them contains the DNA sequence coding for the protein in fusion with the DNA binding domain, the transcription of which is under the control of a constitutive promoter, while another vector contains the DNA sequence coding for the protein in fusion with the activation domain, and the transcription of which is also under the control of a constitutive promoter,
- one of the two above-mentioned vectors, or another vector contains a DNA sequence coding for a protein capable of interacting with the previous ones, and the transcription of which is under the control of a conditional promoter
- one or more of the above-mentioned vectors, or one or more other vectors contain one or more DNA sequences coding for a protein capable of interacting with the preceding ones, and the transcription of which is under the control of a conditional promoter (advantageously different from the previous conditional promoter), or a constitutive promoter.
- the aforementioned method of the invention is carried out using several vectors such as:
- - one of them contains a DNA sequence coding for one of the determined proteins in fusion with the DNA binding domain, and whose transcription is under the control of a constitutive promoter
- another vector contains a DNA sequence coding for another protein determined in fusion with the activation domain, and whose transcription is also under the control of a promoter constitutive,> - one of the two aforementioned vectors, or another vector, contains the DNA sequence coding for the tested protein capable of interacting with the previous ones, and whose transcription is under the control of a conditional promoter
- one or more of the above-mentioned vectors, or one or more other vectors contain one or more DNA sequences coding for another determined protein capable of interacting with the preceding ones, and the transcription of which is under the control of '' a conditional promoter different from the previous conditional promoter, or under the control of a constitutive promoter.
- the detection of an interaction between a protein tested and two determined proteins can be carried out using two vectors such as:
- one of them contains the DNA sequence coding for the protein in fusion with the DNA binding domain
- the other vector contains the DNA sequence coding for the protein in fusion with the activation domain
- one of the two aforementioned vectors contains the DNA sequence coding for the tested protein capable of interacting with the previous ones, and whose transcription is under the control of a conditional promoter.
- the above-mentioned method of the invention for the detection of an interaction between a tested protein and two determined proteins, can also be carried out using three vectors such as:
- the first vector contains the DNA sequence coding for the protein in fusion with the DNA binding domain
- the second vector contains the DNA sequence coding for the protein in fusion with the activation domain
- the third vector contains the DNA sequence coding for the protein tested capable of interacting with the previous ones, and whose transcription is under the control of a conditional promoter.
- the above-mentioned vectors also contain a DNA sequence corresponding to a selection gene, such as a gene encoding an enzyme of the metabolism of a particular amino acid for which the strain of transformed host cells is auxotrophic.
- the host cells transformed by the above-mentioned vectors in the context of the implementation of a method according to the invention are advantageously such that their genome comprises one or more reporter genes, the transcription of which is placed, for each of them, under the control of an operator recognized by the DNA binding domain encoded by one of the above-mentioned vectors, the transcription of these reporter genes taking place when there is formation, if necessary under direct influence or indirect of the protein tested, of a protein complex between the determined proteins produced in the transformed host cells cultured.
- the reporter genes which may be contained in the genome of host cells, there may be mentioned, by way of example:
- ⁇ -galactosidase activity can, for example, result in a blue coloration using 5-bromo-4-chloro-3-indolyl ⁇ -D-galactoside (or Xgal) as substrate, or also in a yellow coloration in using O-nitrophenyl- ⁇ -galactoside (ONPG) as a substrate,
- the host cells used are auxotrophic for the amino acids whose metabolism is dependent on the enzymes encoded by the selection genes contained in the above-mentioned vectors and, if appropriate, for the amino acid whose metabolism is dependent. of the enzyme encoded by a reporter gene contained in the genome of said host cells.
- the host cell strain used is a yeast strain, in particular the yeast strain L40, the genome of which contains, as reporter genes, the HIS3 gene (coding for an enzyme of histidine metabolism) and the LacZ gene coding for ⁇ -galactosidase, the transcription of these reporter genes being under the control of an operator recognized by the LexA DNA binding domain.
- yeast strain L40 the genome of which contains, as reporter genes, the HIS3 gene (coding for an enzyme of histidine metabolism) and the LacZ gene coding for ⁇ -galactosidase, the transcription of these reporter genes being under the control of an operator recognized by the LexA DNA binding domain.
- the DNA sequences coding said determined proteins are chosen from those coding for proteins which form little or no protein complexes with one another.
- the transcription of the reporter gene (s) of said host cells cultured by activating said conditional promoter, or even an increased transcription of this or these reporter gene (s) compared to the transcription of these same genes by repressing said conditional promoter, is then correlated with the detection. a direct or indirect interaction between the protein tested and said proteins determined within the framework of the formation of a protein complex.
- sequences of DNA encoding said determined proteins are chosen from those encoding proteins forming a protein complex therebetween.
- the conditional promoter is the Met25 promoter which can be regulated as a function of the concentration of methionine in the culture medium of the transformed host cells, said promoter being activated in the absence of methionine in the culture medium, and repressed in the presence of methionine, and - the reporter genes contained in the genome of the transformed host cells are:
- a gene encoding an enzyme of the metabolism of a particular amino acid, for which the strain of said host cells is auxotrophic by mutation in said gene “a gene encoding an enzyme responsible for the coloring of culture medium when it reacts with its substrate, such as the LacZ gene encoding ⁇ -galactosidase.
- the detection, or even the measurement, of the growth of the colonies of the strain of host cells transformed in a selective culture medium M1 which, on the one hand does not contain the amino acid whose metabolism is dependent on the enzyme encoded by the reporter gene contained in the genome of said host cells and, on the other hand, does not contain methionine, is correlable with the detection of an interaction between the protein tested and the proteins determined within the framework of the formation of 'A protein complex, insofar as the growth of these colonies in a selective culture medium M2 corresponding to the preceding medium Ml in which methionine is added, is zero or less than that measured in the absence of methionine.
- the detection, or even the measurement, of a coloration in the culture medium of the transformed host cells is correlated with the detection.
- a coloration in the culture medium of the transformed host cells in particular a blue coloration in a medium containing the XGal substrate, but not containing methionine
- the detection is correlated with the detection. of an interaction between the protein tested and the proteins determined within the framework of the formation of a protein complex, insofar as this coloration, in the preceding culture medium in which methionine is added, is zero or less than that measured in the absence of methionine.
- the absence of growth of the colonies of the strain of host cells transformed in the abovementioned Ml culture medium, or the detection of a weaker growth of these colonies in the Ml medium compared to the growth detected for these colonies in the aforementioned M2 medium is correlable to the detection of an interaction between the protein tested and the proteins determined within the framework of the inhibition of the formation of a protein complex.
- the absence of staining in the culture medium of the transformed host cells containing the specific substrate for staining (in particular XGal) but not containing methionine, where the detection of a weaker staining in this culture medium by compared to the culture medium containing methionine, is correlable to the detection of an interaction between the protein tested and the proteins determined within the framework of the inhibition of the formation of a protein complex.
- the present invention more particularly relates to the application of the methods described above to the screening of a cDNA library, or of a degenerate synthetic library of oligonucleotides, said libraries being capable of containing one (or more) sequence (s) of DNA encoding one (or more) protein (s) as described above, interacting directly or indirectly with at least two proteins determined within the framework of the formation of a protein complex , or inhibition of a protein complex.
- the detection of a protein interacting directly or indirectly with two determined proteins A and B, within the framework of the formation of a protein complex, or of the inhibition of the formation of a protein complex is advantageously carried out according to the following method which comprises: the transformation of host cells with:
- a selection gene encoding an enzyme responsible for the metabolism of an amino acid designated below AA2, AA2 being different from AA1, one of the two above-mentioned vectors containing a DNA sequence encoding the protein tested, the transcription of this DNA sequence being under the control of the conditional promoter Met25, said host cells being such that their genome comprises, a reporter gene, in particular the LacZ gene, as well as a gene encoding an enzyme of the. metabolism of an amino acid hereinafter referred to as AA3, AA3 being different from AA1 and AA2, and as they are auxotrophic for the amino acids AA1, AA2 and AA3.
- the DNA sequence coding for the protein tested, or one of the DNA sequences coding for a determined protein is fused, in the vector (s) mentioned above, to a DNA sequence coding for a peptide capable of being recognized specifically by an antibody, in particular a DNA sequence coding for the hemagglutinin tag (HA tag) capable of being recognized by the anti-HA antibody (described in particular in Hanke et al ., 1992).
- a DNA sequence coding for the hemagglutinin tag hemagglutinin tag
- This immunoprecipitation makes it possible to separate and purify the protein complex from the culture medium of said cells, and, if necessary, to verify the structure and / or the biological activity of this complex, in particular to deduce the nature thereof.
- interaction between the protein tested and the proteins determined in the context of the formation of this complex namely: direct or indirect interaction as described above.
- the present invention is not limited to the study of the interaction between three proteins between them, and the method described above in the context of the study of interactions between three proteins, can be adapted to the study of the interaction between four or five proteins (or even more).
- each DNA sequence coding for an additional protein to be tested is introduced into one of the two vectors used in the method described above, or even into other additional vectors, and is advantageously under the control of a conditional promoter preferably different from the other conditional promoter (s) already used to control the transcription of DNA sequences encoding other proteins within the above-mentioned vectors.
- proteins of the multiprotein complex i ⁇ TFIIH essential for the transcription and repair of DNA (Svejstrup et al.,
- pLex9-3H contains an expression cassette consisting of the inducible promoter Met25, a Hemagglutinin tag (HA tag), a localization signal
- the plasmid pVP16 contains a selection marker LEU2 (gene coding for an enzyme of the leucine metabolism) and the transcriptional activator of VP16 cloned downstream of the promoter of ADH.
- the L40 strain [MATa, trpl, his3, leu2, ade2, LYS2:: (LexAop) 4- HIS3, URA3:: (LexAop) g-LacZ] contains the reporter genes HIS3 (coding for an enzyme of histidine metabolism ) and LacZ in merger with an operator recognized by LexA.
- the cells are cultured for 16 hours in complete medium (YPD medium) and transformed with Cdk7-pLex9-
- Two types of controls are available: the growth test and the ⁇ -galactosidase activity test.
- clones isolated from cultures established on HA medium, are suspended in 50 ⁇ ⁇ of sterile water and diluted in cascade from 10 to 10
- a drop of each dilution is deposited on a selective medium for interaction at three (A, containing only adenine) as well as on a medium inhibiting the expression of cyclin H (AM, containing adenine and methionine ImM).
- the ⁇ -galactosidase activity is evaluated on cells having grown overnight in the appropriate medium (the optical density will be measured at 600 nm
- the DO420 is then measured.
- the ⁇ -galactosidase activity (in ml-Lmin-1) is calculated by the formula: (D0 2 o) / [DO 6u0 ) x vol. of culture (ml) x reaction time (min)]. (Rose MD, 1990).
- Ras and Raf are two oncogenic proteins which interact with each other with the consequence of a potential implication in the transduction of signals controlling the phenomena of cell growth and differentiation.
- the contact inhibition of these two proteins can be studied either by screening an oligopeptide library or by involving a third partner identical to one of the two other polypeptides forming the transcriptional activator, but not containing a fusion sequence.
- the third partner will be under the control of the inducible promoter Met25.
- the expression of the Met25 promoter is repressed in the presence of 1 mM Methionine.
- Plasmids derived from pGBT9-3H were constructed as follows: The reading frame (ORF) of H-Ras (V12) (EcoRI-SalI fragment of pBTM116-Ras (Vojtek et al., 1993)) was cloned in phase with the DNA binding domain of GAL4, the resulting plasmid being [pGBT-Ras / Met-0].
- the plasmid [pGBT-Ras / Met-Raf] was obtained by adding on both sides of the EcoRI-BamHI fragment of cRaf-1 originating from the plasmid pGAD-Raf (Van Aelst et a, 1993) a binding sequence containing the NotI cloning site, and then cloning the resulting fragment into the NotI site of the Met25 expression cassette of [pGBT-Ras / Met-0].
- the cells cotransformed with [pGBT-Ras / Met-Raf] and pGAD-Raf are LacZ + (transcription of the ⁇ -galactosidase gene) in the presence of methionine, that is to say under conditions of repression of the Met25 promoter .
- the same cells are LacZ- in the absence of methionine, namely under conditions of derepression of the Met25 promoter.
- the plasmids described above can be used to identify peptides inhibiting an interaction between proteins, for example by expressing a degenerate synthetic library of oligonucleotides under the control of the Met25 promoter.
- the inhibition of the interaction can be detected by a LacZ test under conditions of derepression of the Met25 promoter; the LacZ + phenotype could be restored in the presence of methionine, proving that the inhibition is due to the expression of the Met25 promoter but not to other events such as a mutation.
- pGBT935 the insertion of the cDNA coding for the Ras protein (ch-Ras; Vojtek. 1993) in phase with the coding region of the DNA binding domain GAL4 (GAL-DBD) leads to the plasmid [pGBT935, Met25 -0]; the cDNA coding for the Raf protein (c-Raf-1; Van Aelst, 1993) cloned in phase with the coding region of the nuclear localization site linked to the HA epitope (HA-NLS) in the plasmid [pGBT935, Met25 -0] leads to the plasmid [pGBT935. Met25-Raf].
- the plasmid pGAD-Raf allows the expression of a protein c-Raf-1 fused to the activation domain GAL4 (AD-Raf).
- the vector pLex9-3H derived from the vector pBTMl l ⁇ .
- the pBTM1 l ⁇ part contains, in addition to the sequences necessary for its replication in E. coli, the selection marker TRP1 and the transcriptional activator LexA cloned downstream of the promoter (P) and upstream of the terminator (T) of ADH .
- pLex9-3H also has an expression cassette containing the regulatable promoter Met25. an HA tag, a nuclear localization sequence (NLS), and a tPGK terminator. The insertion sites of the cDNA of interest are indicated.
- the cDNA encoding Cdk7 is cloned in fusion with LexA, that of cyclin H is in fusion with the tag HA, downstream of the regulatable promoter Met25, in the plasmid pLex9-3H whereas the cDNA and MAT1 is cloned in fusion with VP16 in the plasmid pVPl ⁇ .
- LexA that of cyclin H is in fusion with the tag HA, downstream of the regulatable promoter Met25, in the plasmid pLex9-3H
- the cDNA and MAT1 is cloned in fusion with VP16 in the plasmid pVPl ⁇ .
- the latter contains the selection marker
- LEU2 and the activation domain of VP16 downstream of the constitutive promoter ADH.
- A growth test of three yeast clones transformed by the plasmids Cdk7-pLex9-3H-Cyclin H and MAT1-pVP16 on a medium lacking (Met-: methionine derepression) and rich (Met + 1 mM: methionine repression) in methionine.
- the different dilutions are indicated in the center of the figure.
- the cells of the yeast strain HF7c cotransformed with pairs of plasmids are selected in a medium which does not contain tryptophan and leucine (Rose, 1990); the colonies are distributed in a medium which does not contain tryptophan or leucine, and which contains or does not contain methionine. After 24 hours at 30 ° C., the dishes were replicated to test for histidine hypotrophy (results not shown) and for the expression of LacZ (Chardin, 1993), in the presence or absence of metfjionine.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/402,317 US6479237B1 (en) | 1997-04-03 | 1998-04-03 | Methods for detecting interaction among several proteins |
CA002285623A CA2285623A1 (fr) | 1997-04-03 | 1998-04-03 | Methodes de detection d'interactions entre plusieurs proteines |
AU73382/98A AU7338298A (en) | 1997-04-03 | 1998-04-03 | Methods for detecting interaction among several proteins |
JP54126398A JP2001522237A (ja) | 1997-04-03 | 1998-04-03 | 数種のタンパク質間の相互作用を検出する方法 |
EP98920567A EP0977840A2 (fr) | 1997-04-03 | 1998-04-03 | Methodes de detection d'interactions entre plusieurs proteines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/04084 | 1997-04-03 | ||
FR9704084A FR2761697B1 (fr) | 1997-04-03 | 1997-04-03 | Methodes de detection d'interactions entre plusieurs proteines |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998044099A2 true WO1998044099A2 (fr) | 1998-10-08 |
WO1998044099A3 WO1998044099A3 (fr) | 1998-12-30 |
Family
ID=9505488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/000685 WO1998044099A2 (fr) | 1997-04-03 | 1998-04-03 | Methodes de detection d'interactions entre plusieurs proteines |
Country Status (7)
Country | Link |
---|---|
US (1) | US6479237B1 (fr) |
EP (1) | EP0977840A2 (fr) |
JP (1) | JP2001522237A (fr) |
AU (1) | AU7338298A (fr) |
CA (1) | CA2285623A1 (fr) |
FR (1) | FR2761697B1 (fr) |
WO (1) | WO1998044099A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074902B1 (en) | 1998-04-27 | 2006-07-11 | Warf Wisconsin Alumni Research Foundation | Antibody specific for a DNA repair protein |
US7122343B1 (en) * | 1998-04-27 | 2006-10-17 | Wisconsin Alumni Research Foundation | Methods to alter levels of a DNA repair protein |
US20030104427A1 (en) * | 2001-06-25 | 2003-06-05 | Petrini John H.J. | Methods to modulate telomere structure and function |
GB2590302B (en) | 2018-07-06 | 2023-03-22 | The Regents Of The Univ Of Colorado A Body Corporate Existing Under The Laws Of The State Of Colorad | Genetically encoded system for constructing and detecting biologically active agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034646A1 (fr) * | 1994-06-14 | 1995-12-21 | American Cyanamid Company | Nouveaux systemes cellulaires ayant une interaction specifique des paires de liaisons de peptides |
WO1996030507A2 (fr) * | 1995-03-31 | 1996-10-03 | Amersham International Plc | Vecteurs d'expression differentielle |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040855A1 (fr) * | 1996-04-29 | 1997-11-06 | The Johns Hopkins University School Of Medicine | Regulateur de la degradation de l'arn chez les mammiferes induite par des transcrits non-sens |
-
1997
- 1997-04-03 FR FR9704084A patent/FR2761697B1/fr not_active Expired - Fee Related
-
1998
- 1998-04-03 WO PCT/FR1998/000685 patent/WO1998044099A2/fr not_active Application Discontinuation
- 1998-04-03 US US09/402,317 patent/US6479237B1/en not_active Expired - Fee Related
- 1998-04-03 AU AU73382/98A patent/AU7338298A/en not_active Abandoned
- 1998-04-03 CA CA002285623A patent/CA2285623A1/fr not_active Abandoned
- 1998-04-03 EP EP98920567A patent/EP0977840A2/fr not_active Withdrawn
- 1998-04-03 JP JP54126398A patent/JP2001522237A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034646A1 (fr) * | 1994-06-14 | 1995-12-21 | American Cyanamid Company | Nouveaux systemes cellulaires ayant une interaction specifique des paires de liaisons de peptides |
WO1996030507A2 (fr) * | 1995-03-31 | 1996-10-03 | Amersham International Plc | Vecteurs d'expression differentielle |
Non-Patent Citations (8)
Title |
---|
FIELDS S ET AL: "A NOVEL GENETIC SYSTEM TO DETECT PROTEIN-PROTEIN INTERACTIONS" NATURE, vol. 340, 20 juillet 1989, page 245/246 XP002018198 cité dans la demande * |
HINNEN A ET AL: "GENE EXPRESSION IN RECOMBINANT YEAST" 1 janvier 1995 , GENE EXPRESSION IN RECOMBINANT MICROORGANISMS, PAGE(S) 121 - 193 XP000562527 2.2.3 Regulated expression, pages 130-132 Table 3 pages 146-147 * |
JOHNSTON AND DAVIES: "SEQUENCES THAT REGULATE THE DIVERGENT GAL1-GAL10 PROMOTER IN SACCHAROMYCES CEREVISIAE" MOLECULAR AND CELLULAR BIOLOGY, vol. 4, 1984, pages 1440-1448, XP002051282 cité dans la demande * |
KERJAN ET AL.: "Nucleotide sequence of the Saccharomyces cerevisiae MET25 gene" NUCLEIC ACIDS RESEARCH, vol. 14, no. 20, 1986, pages 7861-7871, XP002051281 cité dans la demande * |
LEGRAIN AND CHAPON: "Interaction between PRP11 and SPP91 yeast splicing factors and characterization of a PRP9-PRP11-SPP91 complex" SCIENCE, vol. 262, 1993, pages 108-110, XP002051280 * |
OSBORNE M A ET AL: "THE YEAST TRIBRID SYSTEM - GENETIC DETECTION OF TRANS-PHOSPHORYLATED ITAM-SH2-INTERACTIONS" BIO/TECHNOLOGY, vol. 13, décembre 1995, pages 1474-1478, XP002033515 * |
TIRODE ET AL.: "A CONDITIONALLY EXPRESSED THIRD PARTNER STABILIZES OR PREVENTS THE FORMATION OF A TRANSCRIPTIONAL ACTIVATOR IN A THREE-HYBRID SYSTEM" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 37, 12 septembre 1997, pages 22995-22999, XP002051283 * |
ZHANG J ET AL: "A YEAST THREE-HYBRID METHOD TO CLONE TERNARY PROTEIN COMPLEX COMPONENTS" ANALYTICAL BIOCHEMISTRY, vol. 242, novembre 1996, pages 68-72, XP002038711 cité dans la demande * |
Also Published As
Publication number | Publication date |
---|---|
EP0977840A2 (fr) | 2000-02-09 |
US20020164587A1 (en) | 2002-11-07 |
AU7338298A (en) | 1998-10-22 |
WO1998044099A3 (fr) | 1998-12-30 |
CA2285623A1 (fr) | 1998-10-08 |
FR2761697A1 (fr) | 1998-10-09 |
JP2001522237A (ja) | 2001-11-13 |
FR2761697B1 (fr) | 1999-05-28 |
US6479237B1 (en) | 2002-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Criekinge et al. | Yeast two-hybrid: state of the art | |
Kuras et al. | A heteromeric complex containing the centromere binding factor 1 and two basic leucine zipper factors, Met4 and Met28, mediates the transcription activation of yeast sulfur metabolism. | |
Le et al. | Two new S‐phase‐specific genes from Saccharomyces cerevisiae | |
Ii et al. | Mus81 functions in the quality control of replication forks at the rDNA and is involved in the maintenance of rDNA repeat number in Saccharomyces cerevisiae | |
Fulgosi et al. | A novel multi-functional chloroplast protein: identification of a 40 kDa immunophilin-like protein located in the thylakoid lumen | |
JP3537141B2 (ja) | 新種蛋白質分離のための相互作用を用いる補捉システム | |
Behrsin et al. | Functionally important residues in the peptidyl-prolyl isomerase Pin1 revealed by unigenic evolution | |
JPH11502717A (ja) | 逆ツーハイブリッドシステム | |
CA2236867A1 (fr) | Procedes d'identification de composes pour la rupture des interactions entre proteines | |
JPH10500865A (ja) | タンパク質−rna相互作用の検出システム | |
Jansen et al. | Mutations in the SAM domain of STE50 differentially influence the MAPK-mediated pathways for mating, filamentous growth and osmotolerance in Saccharomyces cerevisiae | |
El Bakkoury et al. | Recruitment of the yeast MADS‐box proteins, ArgRI and Mcm1 by the pleiotropic factor ArgRIII is required for their stability | |
CA2246300A1 (fr) | Essai a base de cellules | |
US6074829A (en) | Relating to assay systems | |
US6326150B1 (en) | Yeast interaction trap assay | |
Su-Jin et al. | Role of RNA polymerase II carboxy terminal domain phosphorylation in DNA damage response | |
EP1049775B1 (fr) | Proteine humaine btrcp | |
JPH08509132A (ja) | ガゼインキナーゼ▲i▼と相互作用するタンパク質に関連する方法および物質 | |
WO1998044099A2 (fr) | Methodes de detection d'interactions entre plusieurs proteines | |
JP2001501809A (ja) | カンディダ アルビカンスからの新規tfiib転写ファクター、それをコード化する核酸配列、及びカンディダ アルビカンス増殖の阻害のためのスクリーニング方法 | |
Hart et al. | Analysis of the NF-κB p50 dimer interface by diversity screening | |
Cowell | Yeast two-hybrid library screening | |
Binkowski et al. | Ligand-regulated peptides: a general approach for modulating protein-peptide interactions with small molecules | |
JP2003517307A (ja) | ユビキチン−リガーゼscf複合体の活性化を調節し得る化合物の細胞スクリーニング方法及びその使用 | |
WO2005093086A1 (fr) | PROCEDE DE CRIBLAGE D'AGENTS MODULANT L'UBIQUITINATION DE LA PROTEINE IkBα ET MOYENS DESTINES A LA MISE EN OEUVRE DUDIT PROCEDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998920567 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2285623 Country of ref document: CA Ref country code: CA Ref document number: 2285623 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 541263 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998920567 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09402317 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998920567 Country of ref document: EP |